UK biotech hands off mid-stage C. dif­fi­cile drug in up to $570M deal

A biotech in the UK has out-li­censed a C. dif­fi­cile can­di­date to a US biotech for fur­ther clin­i­cal and com­mer­cial­iza­tion ef­forts.

UK-based Des­tiny Phar­ma an­nounced …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER